SecBot SecBot
6-K ·Filed Jul 27, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001654954-26-006895
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor forthcoming medical meeting presentation for detailed efficacy/safety data and regulatory submissions (FDA, EMA, China). Positive OS data supports label expansion and could meaningfully boost AZN's oncology revenue trajectory, though the PFS miss may introduce some skepticism. Expect increased analyst attention on AZN's ADC pipeline.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$169.64
T+0 close · Jul 27, 2026 · via day close
Latest settled
−0.48%
T+60 · $168.82
Vs SPY
−4.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $169.64entry
  2. T+1 · 4mo ago +1.67%α +1.43% · $172.48
  3. T+5 · 4mo ago 0.00%α −1.07% · $169.64
  4. T+20 · 3mo ago −1.75%α −5.05% · $166.68
  5. T+60 · 28d ago −0.48%α −4.54% · $168.82
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced positive Phase III results for its wholly owned ADC, Sone-Ve (sonesitatug vedotin), demonstrating a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers. This is the first pivotal readout from AZN's wholly owned ADC portfolio and the first Phase III trial to show an OS benefit with an anti-CLDN18.2 ADC in this setting, potentially expanding the treatable population to ~60% of patients with CLDN18.2 expression ≥25%. The PFS endpoint showed a trend but did not reach statistical significance, though the OS win in a large unmet need is a major positive for AZN's oncology pipeline.

Key Facts

  • Sone-Ve met the dual primary endpoint of OS in 3rd and later-line treatment and the key secondary endpoint of OS in the overall 2nd and later-line population (statistically significant, highly clinically meaningful)
  • PFS by BICR showed a trend toward improvement but did not reach statistical significance
  • First Phase III trial to show OS benefit with an anti-CLDN18.2 ADC in gastric/GEJ cancers
  • Trial included patients with CLDN18.2 expression on ≥25% of tumor cells, expanding the potential addressable population to ~60% of patients
  • ~183,500 patients annually in US, EU, China, Japan treated in 2nd and later-line for advanced CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers
  • Sone-Ve has Orphan Drug Designation from FDA and European Commission, and Breakthrough Designation in China
  • First pivotal readout from AstraZeneca's wholly owned ADC portfolio

Financial Impact

Potentially significant new revenue stream for AZN targeting a large gastric cancer market (~183,500 patients annually in major markets) with limited 2nd-line options; no financial figures disclosed in filing

pipeline valuerevenue potentialmarket share in gastric cancer

Risk Factors

  • PFS endpoint did not reach statistical significance, which could limit regulatory claims or payer coverage
  • Regulatory approval and label scope are not guaranteed; competition from other CLDN18.2-targeted agents (e.g., zolbetuximab) could emerge
  • Safety profile needs full disclosure; no new safety signals identified but tolerability in a broader population remains to be seen

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006895
Document: 0001654954-26-006895-index-headers.html0001654954-26-006895
Document: 0001654954-26-006895-index.html0001654954-26-006895
Document: 0001654954-26-006895.txt0001654954-26-006895

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026